Precision Pathology Services and bioAffinity Technologies Announce Initiation of CLIA Validation for Non-Invasive Early Lung Cancer Test

PUBLISHED ON August 12, 2020

AUGUST 12, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company advancing cutting-edge cancer diagnostics, and Precision Pathology Services, a CAP/CLIA-certified anatomic and clinical pathology laboratory, announced the initiation of CLIA validation for CyPath® Lung, a non-invasive flow cytometric test for early-stage lung cancer.  Precision Pathology has licensed bioAffinity’s intellectual property for the development of CyPath® Lung as a laboratory-developed test (LDT).

read more

SA Biotech Nearing Launch of Breakthrough Cancer Test

PUBLISHED ON August 11, 2020

San Antonio Business Journal (August 11, 2020) A local pathology practice has initiated a validation study of San Antonio-based bioAffinity Technologies' CyPath Lung early detection cancer test. The validation study is needed for bioAffinity to commercialize the product, which is its first.

read more

bioAffinity Technologies Announces Poster Presentation at CYTO 2020 Conference

PUBLISHED ON August 4, 2020

AUGUST 4, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced its presentation of a poster explaining the Company’s use of flow cytometry for diagnosis of lung disease including cancer at the International Society for Advancement of Cytometry CYTO 2020 to be held virtually on August 4-5, 2020.

read more

bioAffinity Technologies Announces Closing of $5,000,000 Convertible Note Financing

PUBLISHED ON July 28, 2020

JULY 28, 2020 (San Antonio, TX) bioAffinity Technologies, a privately-held biotech company, today announced it has closed a non-brokered, secured convertible note ("Note") financing for proceeds of $5,000,000.00 (the "Offering").  The proceeds from the Note are funding operations to advance the Company’s non-invasive CyPath® Lung cancer test and therapeutic research and development of novel drug candidates for the selective treatment of multiple cancers.

read more

Stephen Squinto, PhD., named Vice Chairman of bioAffinity Technologies

PUBLISHED ON July 7, 2020

JULY 7, 2020 (San Antionio, TX) bioAffinity Technologies, a privately-held cancer diagnostics and therapeutics company, today announced that Stephen Squinto, Ph.D., has been named Vice Chairman of the Company’s Board of Directors, and David Elzi, Ph.D., has been appointed Vice President of Research in recognition of Dr. Elzi’s pivotal role in the Company’s scientific discoveries related to cancer therapeutics.

read more

bioAffinity Technologies was selected as one of San Antonio’s Top 2020 Innovators. In this video, you will see Maria Zannes, President and Chief Executive Officer, speak about what drives motivation, innovation and success and kick off San Antonio’s premier annual event celebrating the City’s healthcare and bioscience industry.

 

www.thehealthcell.org/sitepage/state-of-the-industry/